erbB-2 Antibody
| Code | Size | Price |
|---|
| PSI-5153-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5153-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Chicken
Antibody Isotype: IgY
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
erbB-2 Antibody: NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu, MLN19, NEU, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein
Application Note:
erbB-2 antibody can be used for detection of erbB-2 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
erbB-2 Antibody: The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.
Background References:
- Baselga J and Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Rev.2009; 9:463-475.
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987; 235:177-82.
- Vermeij J, Teugels E, Bourgain C, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer2008; 8:3.
- Marmor MD, Skaria KB, and Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Rad. Oncol. Biol. Phys.2004; 58:903-13.
Buffer:
erbB-2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
erbB-2 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human erbB-2.
The immunogen is located within the last 50 amino acids of erbB-2.
The immunogen is located within the last 50 amino acids of erbB-2.
NCBI Gene ID #:
2064
NCBI Official Name:
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
NCBI Official Symbol:
ERBB2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_004439
Protein GI Number:
54792096
Purification:
erbB-2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer
Swissprot #:
P04626
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | erbB-2 Peptide | PSI-5153P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|